Barrow Hanley Mewhinney & Strauss LLC significantly reduced its stake in Merck & Co., Inc. (NYSE: MRK) during the third quarter of 2026, selling 5,117,489 shares and retaining 2,213,929 shares. The institutional investor now holds about 0.09% of Merck, valued at $321,706,000, according to its latest SEC filing.
Other institutional investors have adjusted their positions in Merck as well. BlackRock Inc. increased its stake by 0.5% in the second quarter, owning 226,999,837 shares worth $29,169,479,000. State Street Corp grew its holdings by 0.8% in the third quarter, now owning 121,422,392 shares valued at $17,745,131,000. Wellington Management Group LLP increased its stake by 2.3% in the second quarter, holding 86,249,283 shares worth $11,083,033,000. Fisher Asset Management LLC grew its position by 8.3% in the third quarter, now owning 41,699,432 shares valued at $6,059,345,000. Bank of America Corp DE increased its stake by 10.5% in the first quarter, holding 30,774,221 shares worth $3,701,831,000.
Analysts have recently issued mixed ratings on Merck. Berenberg Bank raised its price target from $127.00 to $137.00 but maintained a "hold" rating. Argus initiated coverage with a "strong-buy" rating. UBS Group increased its price target from $145.00 to $175.00 with a "buy" rating. Daiwa Securities Group upgraded Merck from "neutral" to "outperform" with a $143.00 price target. Wells Fargo & Company boosted its price objective from $150.00 to $170.00 with an "overweight" rating. The stock currently has a consensus rating of "Moderate Buy" and an average target price of $155.74.
Merck reported strong third-quarter earnings, with $2.49 earnings per share, exceeding estimates of $2.09. The company's revenue was $18.09 billion, up 4.7% from the same period last year. Merck also increased its quarterly dividend to $0.88, representing a $3.52 annualized dividend and a yield of 2.6%. The ex-dividend date is December 15, 2026.